DK3387019T3 - Relaxin-immunoglobulinfusionsproteiner og anvendelsesfremgangsmåder - Google Patents
Relaxin-immunoglobulinfusionsproteiner og anvendelsesfremgangsmåder Download PDFInfo
- Publication number
- DK3387019T3 DK3387019T3 DK16873899.5T DK16873899T DK3387019T3 DK 3387019 T3 DK3387019 T3 DK 3387019T3 DK 16873899 T DK16873899 T DK 16873899T DK 3387019 T3 DK3387019 T3 DK 3387019T3
- Authority
- DK
- Denmark
- Prior art keywords
- relaxin
- methods
- proteins
- immunoglobulin infusion
- immunoglobulin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/64—Relaxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
- C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562265344P | 2015-12-09 | 2015-12-09 | |
| PCT/US2016/065779 WO2017100540A2 (en) | 2015-12-09 | 2016-12-09 | Relaxin immunoglobulin fusion proteins and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3387019T3 true DK3387019T3 (da) | 2022-01-10 |
Family
ID=59013561
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16873899.5T DK3387019T3 (da) | 2015-12-09 | 2016-12-09 | Relaxin-immunoglobulinfusionsproteiner og anvendelsesfremgangsmåder |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11161891B2 (da) |
| EP (2) | EP3387019B1 (da) |
| DK (1) | DK3387019T3 (da) |
| ES (1) | ES2903257T3 (da) |
| PT (1) | PT3387019T (da) |
| WO (1) | WO2017100540A2 (da) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3387019B1 (en) | 2015-12-09 | 2021-10-20 | The Scripps Research Institute | Relaxin immunoglobulin fusion proteins and methods of use |
| EP3522911B1 (en) * | 2016-10-07 | 2021-12-08 | Beth Israel Deaconess Medical Center, Inc. | Compositions comprising relaxin and methods of use thereof |
| CA3100829A1 (en) * | 2018-05-23 | 2019-11-28 | Pfizer Inc. | Antibodies specific for gucy2c and uses thereof |
| TW202434620A (zh) * | 2019-07-31 | 2024-09-01 | 美商美國禮來大藥廠 | 鬆弛素(relaxin)類似物及其使用方法 |
| CN115461374A (zh) * | 2020-02-12 | 2022-12-09 | 斯克利普斯研究所 | 长效gm-csf和使用方法 |
| CA3186143A1 (en) * | 2020-06-17 | 2021-12-23 | Medimmune Limited | Heterodimeric relaxin fusions and uses thereof |
| EP4429694A4 (en) * | 2021-11-11 | 2025-10-01 | Tectonic Operating Company Inc | RELAXIN-2 FUSION PROTEIN ANALOGUES AND METHODS OF USE THEREOF |
| JP2025540294A (ja) * | 2022-12-09 | 2025-12-11 | アストラゼネカ・アクチエボラーグ | ヘテロ二量体リラキシン融合体を使用する投薬レジメン |
| JP7835367B2 (ja) * | 2023-05-18 | 2026-03-25 | テクトニク オペレーティング カンパニー，インコーポレイテッド | リラキシン－２融合タンパク質類似体及びそれを使用する方法 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| US6565841B1 (en) | 1991-03-15 | 2003-05-20 | Amgen, Inc. | Pulmonary administration of granulocyte colony stimulating factor |
| WO1993015722A1 (en) | 1992-02-07 | 1993-08-19 | Syntex (Usa) Inc. | Controlled delivery of pharmaceuticals from preformed porous microparticles |
| US6372716B1 (en) | 1994-04-26 | 2002-04-16 | Genetics Institute, Inc. | Formulations for factor IX |
| US5911997A (en) | 1995-06-07 | 1999-06-15 | Connetics Corporation | Relaxin-like factor and methods and uses thereof |
| US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| ATE228004T1 (de) | 1995-08-15 | 2002-12-15 | Connetics Corp | Verwendung von relaxin zur stimulierung der angiogenese |
| US6566329B1 (en) | 1999-06-28 | 2003-05-20 | Novo Nordisk A/S | Freeze-dried preparation of human growth hormone |
| CA2379388C (en) | 1999-07-13 | 2012-05-29 | George N. Cox, Iii | Immunoglobulin fusion proteins |
| DK1265928T3 (da) * | 2000-01-27 | 2010-11-15 | Medimmune Llc | RSV-neutraliserende antistoffer med ultra høj affinitet |
| CA2397200C (en) | 2000-02-09 | 2010-11-23 | Connetics Corporation | Use of relaxin to treat diseases related to vasoconstriction |
| AU2012211451A1 (en) | 2000-03-01 | 2012-08-30 | Applied Molecular Evolution, Inc. | High potency recombinant antibodies and method for producing them |
| EP1259547B1 (en) | 2000-03-01 | 2012-07-11 | Medimmune, Inc. | High potency recombinant antibodies and method for producing them |
| AU1994402A (en) * | 2000-11-28 | 2002-06-11 | Mediummune Inc | Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment |
| US6992174B2 (en) | 2001-03-30 | 2006-01-31 | Emd Lexigen Research Center Corp. | Reducing the immunogenicity of fusion proteins |
| CA2382766A1 (en) | 2001-04-20 | 2002-10-20 | Azad Kaushik | Novel bovine vdj cassette, bf1h1, suitable for antigenization |
| US20080260731A1 (en) | 2002-03-01 | 2008-10-23 | Bernett Matthew J | Optimized antibodies that target cd19 |
| US20050186526A1 (en) | 2002-11-01 | 2005-08-25 | Bas Medical, Inc. | Methods and systems for enabling and stabilizing tooth movement |
| US6984128B2 (en) | 2002-11-01 | 2006-01-10 | Bas Medical, Inc. | Methods for enabling and stabilizing tooth movement |
| US7189539B2 (en) | 2003-11-25 | 2007-03-13 | Bristol-Myers Squibb Company | Polynucleotide encoding a human relaxin receptor, HGPRBMY5v1 |
| US7878978B2 (en) | 2004-03-18 | 2011-02-01 | University Of Pittsburgh- Of The Commonwealth System Of Higher Education | Use of relaxin to increase arterial compliance |
| JP4836942B2 (ja) | 2004-04-30 | 2011-12-14 | コーセラ， インコーポレイテッド | リラキシンの調節による胎仔の発育の制御のための方法および組成物 |
| TW200636064A (en) | 2004-10-28 | 2006-10-16 | Centocor Inc | Anti-respiratory syncytial virus antibodies, antigens and uses thereof |
| EP2023935A4 (en) | 2006-06-03 | 2010-12-22 | Cylene Pharmaceuticals Inc | METHOD FOR THE ADMINISTRATIVE MEDICINE |
| WO2009140433A1 (en) | 2008-05-16 | 2009-11-19 | Corthera, Inc. | Method of promoting wound healing |
| WO2009140657A2 (en) | 2008-05-16 | 2009-11-19 | Corthera, Inc. | Method of treating chronic heart failure |
| AU2009246116B2 (en) | 2008-05-16 | 2013-02-14 | Corthera, Inc. | Method of preventing premature delivery |
| SG10201609580YA (en) | 2008-05-16 | 2016-12-29 | Corthera Inc | Treating dyspnea associated with acute heart failure with relaxin |
| PT3903829T (pt) | 2009-02-13 | 2023-06-02 | Immunomedics Inc | Imunoconjugados com uma ligação intracelular clivável |
| AU2010226392B9 (en) | 2009-03-20 | 2014-05-22 | Amgen Inc. | Selective and potent peptide inhibitors of Kv1.3 |
| MX2012010382A (es) | 2010-03-10 | 2013-01-29 | Univ Melbourne | Modulacion de acuaporinas con relaxina. |
| US20110243942A1 (en) | 2010-04-02 | 2011-10-06 | Athena Discovery, Inc. | Relaxin-fusion proteins with extended in vivo half-lives |
| WO2012169822A2 (ko) | 2011-06-10 | 2012-12-13 | 강원대학교산학협력단 | 암세포 증식 억제와 혈관신생 억제를 위한 융합 단백질 및 이를 포함한 항암 조성물 |
| JP2014523871A (ja) | 2011-06-10 | 2014-09-18 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 膵臓ベータ細胞増殖の調整 |
| CN103930440A (zh) | 2011-07-01 | 2014-07-16 | 拜耳知识产权有限责任公司 | 松弛素融合多肽及其用途 |
| WO2013007563A1 (en) | 2011-07-08 | 2013-01-17 | Bayer Intellectual Property Gmbh | Fusion proteins releasing relaxin and uses thereof |
| EP2802603A4 (en) | 2012-01-09 | 2015-11-04 | Scripps Research Inst | REGIONS DETERMINING ULTRALONGUAL COMPLEMENTARYITY AND USES THEREOF |
| US20150011431A1 (en) | 2012-01-09 | 2015-01-08 | The Scripps Research Institute | Humanized antibodies |
| US9273093B2 (en) | 2012-10-11 | 2016-03-01 | Protagonist Therapeutics, Inc. | α4β7 peptide dimer antagonists |
| WO2014110368A1 (en) | 2013-01-11 | 2014-07-17 | The California Institute For Biomedical Research | Bovine fusion antibodies |
| PT3019533T (pt) | 2013-07-11 | 2020-04-17 | Scripps Research Inst | Proteínas de fusão de imunoglobulinas de hélices super-enroladas e composições das mesmas |
| KR20170010893A (ko) | 2014-06-06 | 2017-02-01 | 더 캘리포니아 인스티튜트 포 바이오메디칼 리써치 | 아미노 말단 면역글로불린 융합 단백질 및 이의 조성물을 구축하는 방법 |
| EP3387019B1 (en) | 2015-12-09 | 2021-10-20 | The Scripps Research Institute | Relaxin immunoglobulin fusion proteins and methods of use |
| WO2018013483A1 (en) | 2016-07-11 | 2018-01-18 | The California Institute For Biomedical Research | Kv1.3 channel blocking peptides and uses thereof |
-
2016
- 2016-12-09 EP EP16873899.5A patent/EP3387019B1/en active Active
- 2016-12-09 PT PT168738995T patent/PT3387019T/pt unknown
- 2016-12-09 DK DK16873899.5T patent/DK3387019T3/da active
- 2016-12-09 ES ES16873899T patent/ES2903257T3/es active Active
- 2016-12-09 EP EP21203381.5A patent/EP4011919A3/en not_active Withdrawn
- 2016-12-09 US US16/060,384 patent/US11161891B2/en active Active
- 2016-12-09 WO PCT/US2016/065779 patent/WO2017100540A2/en not_active Ceased
-
2021
- 2021-08-26 US US17/458,136 patent/US12275771B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP4011919A3 (en) | 2022-10-12 |
| WO2017100540A3 (en) | 2017-07-20 |
| PT3387019T (pt) | 2022-01-14 |
| EP3387019B1 (en) | 2021-10-20 |
| US20190263882A1 (en) | 2019-08-29 |
| US11161891B2 (en) | 2021-11-02 |
| WO2017100540A2 (en) | 2017-06-15 |
| EP3387019A2 (en) | 2018-10-17 |
| EP4011919A2 (en) | 2022-06-15 |
| US20220048969A1 (en) | 2022-02-17 |
| ES2903257T3 (es) | 2022-03-31 |
| US12275771B2 (en) | 2025-04-15 |
| EP3387019A4 (en) | 2019-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202004919B (en) | Anti-tigit antigen-binding proteins and methods of use thereof | |
| DK3653221T5 (da) | Anti-pvrig-antistoffer og anvendelsesfremgangsmåder | |
| DK3353210T3 (da) | Anti-TIGIT-antistoffer og fremgangsmåder til anvendelse | |
| IL259747A (en) | Antibodies targeting fc receptor-like 5 and methods of use | |
| IL255269A (en) | Compositions of obeticholic acid and methods of use | |
| DK3303386T3 (da) | Anti-Tau-antistoffer og fremgangsmåder til anvendlelse | |
| DK3215532T3 (da) | Anti-TIM3-antistoffer og fremgangsmåder til anvendelse | |
| DK3283106T3 (da) | Terapeutiske antistoffer og anvendelser deraf | |
| DK3436048T3 (da) | Neoantigener og fremgangsmåder til anvendelse deraf | |
| DK3356404T3 (da) | Anti-pd1-antistoffer og fremgangsmåder til anvendelse | |
| IL251970B (en) | Anti-cd79b antibodies and methods of use | |
| IL251972B (en) | Analyzing and utilizing landscapes | |
| DK3317284T3 (da) | Benzoxazepin-oxazolidinonforbindelser og fremgangsmåder til anvendelse | |
| DK3390444T3 (da) | Anti-tl1a-antigenbindende proteiner og anvendelser deraf | |
| DK3235830T3 (da) | Interleukin-15-proteinkompleks og anvendelse deraf | |
| DK3259597T3 (da) | Pvrig-polypeptider og fremgangsmåder til behandling | |
| IL246383A0 (en) | Polyoxometalate and heteropolyoxometalate compositions and methods for their use | |
| DK3828194T3 (da) | Oxysteroler og fremgangsmåder til anvendelse deraf | |
| DK3394065T3 (da) | Tetrahydropyranyl-amino-pyrrolopyrimidinon og fremgangsmåder til anvendelse deraf | |
| PL3250610T3 (pl) | Przeciwciała anty-FcRn i sposoby ich stosowania | |
| DK3368655T3 (da) | Forbedret proteinekspression og fremgangsmåder dertil | |
| IL254670A0 (en) | Humanized anti-c1s antibodies and methods of use thereof | |
| DK3525583T3 (da) | Anti-c1s-antistoffer og fremgangsmåder til anvendelse deraf | |
| IL256531B (en) | Oxysterols and methods of use thereof | |
| DK3514151T3 (da) | Proteinkinase-C-hæmmere og fremgangsmåder til anvendelse deraf |